Dasatinib Plus Anti-CD19/CD22 Bispecific CAR-T Cell Therapy for Elderly Ph-positive ALL Patients
Clinical trial NCT05523661 · UNKNOWN
Trial details
- NCT number
- NCT05523661
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-03-01
- Primary completion
- 2025-03-01
- Enrollment
- 15
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.